Igene Biotechnology, Inc. Stocks

$ 0Last Updated 10.04.2026

Issuer Rating

Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 15654

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Igene Biotechnology, Inc. focuses on the research, development, production, and commercialization of specialty ingredients for human and animal nutrition. The company supplies natural astaxanthin, a nutrient used as a source of pigment for coloring farmed salmon and trout species. It also supplies ingredients and finished products to the nutraceutical and feed industry. The company also provides research and development services for microbial strain improvement and fermentation process development and scale up from shake flask, to pilot plant, to commercial sized fermentors; and analytical chemistry services for identification and quantization of carotenoids in foods, feeds, and animal tissues, including verification of wild versus farm raised salmonids. The company was formerly known as IGI Biotechnology, Inc. and changed its name to IGENE Biotechnology, Inc. in April 1986. IGENE Biotechnology, Inc. was founded in 1981 and is based in Columbia, Maryland.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks